Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares
dc.contributor.author | Higgins, Peter D.R. | en_US |
dc.contributor.author | Rubin, D. T. | en_US |
dc.contributor.author | Kaulback, K. | en_US |
dc.contributor.author | Schoenfield, P. S. | en_US |
dc.contributor.author | Kane, Sunanda V. | en_US |
dc.date.accessioned | 2010-06-01T21:29:10Z | |
dc.date.available | 2010-06-01T21:29:10Z | |
dc.date.issued | 2009-02 | en_US |
dc.identifier.citation | HIGGINS, P. D. R.; RUBIN, D. T.; KAULBACK, K.; SCHOENFIELD, P. S.; KANE, S. V. (2009). "Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares." Alimentary Pharmacology & Therapeutics 29(3): 247-257. <http://hdl.handle.net/2027.42/74543> | en_US |
dc.identifier.issn | 0269-2813 | en_US |
dc.identifier.issn | 1365-2036 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/74543 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18945258&dopt=citation | en_US |
dc.format.extent | 270802 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | Journal compilation © 2009 Blackwell Publishing Ltd | en_US |
dc.title | Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Otolaryngology | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | * Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | † Department of Internal Medicine, University of Chicago Medical Center, Chicago, IL, USA | en_US |
dc.contributor.affiliationother | † Research in Practice, Toronto, ON, Canada | en_US |
dc.contributor.affiliationother | § Division of Gastroenterology, Ann Arbor Veterans Affairs Medical Center and Center for Excellence in Health Services Research, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | ¶ Division of Gastroenterology, Mayo Clinic, Rochester, MN, USA | en_US |
dc.identifier.pmid | 18945258 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/74543/1/j.1365-2036.2008.03865.x.pdf | |
dc.identifier.doi | 10.1111/j.1365-2036.2008.03865.x | en_US |
dc.identifier.source | Alimentary Pharmacology & Therapeutics | en_US |
dc.identifier.citedreference | Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004; 27: 1218 – 24. | en_US |
dc.identifier.citedreference | Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med 2003; 157: 249 – 55. | en_US |
dc.identifier.citedreference | Loghman-Adham M. Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care 2003; 9: 155 – 71. | en_US |
dc.identifier.citedreference | Peura D. Helicobacter pylori: rational management options. Am J Med 1998; 105: 424 – 30. | en_US |
dc.identifier.citedreference | DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002; 40: 794 – 811. | en_US |
dc.identifier.citedreference | WHO. Adherence to Long-Term Therapies. Evidence for Action [Internet], Vol. 2008. Geneva: World Health Organization, 2003. | en_US |
dc.identifier.citedreference | Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J 1995; 130: 572 – 9. | en_US |
dc.identifier.citedreference | Morris A, Brennan G, MacDonald T, Donnan P. Population-based adherence to prescribed medication in type 2 diabetes: a cause for concern. Diabetes 2000; 49: A76. | en_US |
dc.identifier.citedreference | Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296 – 310. | en_US |
dc.identifier.citedreference | Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease [ see comment ]. Am J Gastroenterol 2007; 102: 1417 – 26. | en_US |
dc.identifier.citedreference | Cerveny P, Bortlik M, Kubena A, Vlcek J, Lakatos PL, Lukas M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 2007; 13: 1244 – 9. | en_US |
dc.identifier.citedreference | Lopez SR, Bermejo F, Carrera E, Perez-Abad M, Boixeda D. Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig 2005; 97: 249 – 57. | en_US |
dc.identifier.citedreference | Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 191 – 8. | en_US |
dc.identifier.citedreference | Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease [ see comment ]. Am J Gastroenterol 2003; 98: 1535 – 44. | en_US |
dc.identifier.citedreference | Bernal I, Domenech E, Garcia-Planella E, et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci 2006; 51: 2165 – 9. | en_US |
dc.identifier.citedreference | Nigro G, Angelini G, Grosso SB, Caula G, Sategna-Guidetti C. Psychiatric predictors of noncompliance in inflammatory bowel disease: psychiatry and compliance. J Clin Gastroenterol 2001; 32: 66 – 8. | en_US |
dc.identifier.citedreference | van Hees PA, van Tongeren JH. Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol 1982; 4: 333 – 6. | en_US |
dc.identifier.citedreference | Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis [Review] [59 refs]. Aliment Pharmacol Ther 2006; 23: 577 – 85. | en_US |
dc.identifier.citedreference | Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 39 – 43. | en_US |
dc.identifier.citedreference | Moody GA, Jayanthi V, Probert CS, Mac KH, Mayberry JF. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 1179 – 83. | en_US |
dc.identifier.citedreference | Rubin DT, Lashner BA. Will a 5-ASA a day keep the cancer (and dysplasia) away? Am J Gastroenterol 2005; 100: 1354 – 6. | en_US |
dc.identifier.citedreference | Rubin DT, Cruz-Correa MR, Gasche C, et al. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis 2008; 14: 265 – 74. | en_US |
dc.identifier.citedreference | Velayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006; 130: 1941 – 9. | en_US |
dc.identifier.citedreference | Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 1345 – 53. | en_US |
dc.identifier.citedreference | Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 1988; 26: 814 – 23. | en_US |
dc.identifier.citedreference | Hall NJ, Rubin GP, Hungin APS, Dougall A. Medication beliefs among patients with inflammatory bowel disease who report low quality of life: a qualitative study. BMC Gastroenterol. 2007; 7: 20. | en_US |
dc.identifier.citedreference | Loftus EV Jr. A practical perspective on ulcerative colitis: patients’ needs from aminosalicylate therapies. Inflamm Bowel Dis 2006; 12: 1107 – 13. | en_US |
dc.identifier.citedreference | Klugmann HJ, Giehler B, Lohmann D, Schiedewitz W. Individualized sulfasalazine treatment of ulcerative colitis and monitoring of patient compliance by determining sulfapyridine serum concentration [German]. Gastroenterol J 1990; 49: 160 – 4. | en_US |
dc.identifier.citedreference | Bokemeyer B, Teml A, Roggel C, et al. Adherence to thiopurine treatment in out-patients with Crohn’s disease. Aliment Pharmacol Ther 2007; 26: 217 – 25. | en_US |
dc.identifier.citedreference | Cerveny P, Lukas M, Bortlik M, Kubena A, Vlcek J Non-adherence to medicamentuous treatment of inflammatory bowel disease and its most frequent forms. Cesk Gastroenterol Hepatol 2006; 60: 207 – 12 [Czech]. | en_US |
dc.identifier.citedreference | Bertomoro P, Vettorato M, Mazzocco K, Rumiati R, Sturniolo G, D’Inca R. Adherence to Medication in Inflammatory Bowel Disease Patients. Digestive Disease Week, Vol. 132. Washington, DC: American Gastroenterological Association, 2007: A344. | en_US |
dc.identifier.citedreference | Mackner LM, Crandall WV. Oral medication adherence in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 1006 – 12. | en_US |
dc.identifier.citedreference | Oliva-Hemker MM, Abadom V, Cuffari C, Thompson RE. Nonadherence with thiopurine immunomodulator and mesalamine medications in children with Crohn disease. J Pediatr Gastroenterol Nutr 2007; 44: 180 – 4. | en_US |
dc.identifier.citedreference | Waters BM, Jensen L, Fedorak RN. Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial. Can J Gastroenterol. 2005; 19: 235 – 44. | en_US |
dc.identifier.citedreference | Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003; 1: 170 – 3. | en_US |
dc.identifier.citedreference | Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet 1980; 1: 514. | en_US |
dc.identifier.citedreference | Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2: 1041 – 8. | en_US |
dc.identifier.citedreference | Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci 2008; 53: 1020 – 4. | en_US |
dc.identifier.citedreference | Kane S, Shaya F, El-Khoury A. Poor compliance with 5-ASA therapy in patients with gastrointestinal disorders increases the burden on healthcare services: a retrospective survey in Maryland, USA. In: America CsaCFo, ed. Advances in IBD, Vol. 13. Miami, FL: Crohn’s and Colitis Foundation of America, 2007: 664. | en_US |
dc.identifier.citedreference | Fendrick AM, Smith DG, Chernew ME, Shah SN. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care 2001; 7: 861 – 7. | en_US |
dc.identifier.citedreference | Fendrick AM, Chernew ME. Value-based insurance design: a “clinically sensitive, fiscally responsible” approach to mitigate the adverse clinical effects of high-deductible consumer-directed health plans. J Gen Intern Med 2007; 22: 890 – 1. | en_US |
dc.identifier.citedreference | Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med 2005; 143: 89 – 99. | en_US |
dc.identifier.citedreference | Levy RL, Feld AD. Increasing patient adherence to gastroenterology treatment and prevention regimens. Am J Gastroenterol 1999; 94: 1733 – 42. | en_US |
dc.identifier.citedreference | Kane S. Medication adherence and the physician-patient relationship. Am J Gastroenterol 2002; 97: 1853. | en_US |
dc.identifier.citedreference | Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007; 167: 540 – 50. | en_US |
dc.identifier.citedreference | Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881 – 4. | en_US |
dc.identifier.citedreference | Brun J. Patient compliance with once-daily and twice-daily oral formulations of 5-isosorbide mononitrate: a comparative study. J Int Med Res 1994; 22: 266 – 72. | en_US |
dc.identifier.citedreference | Kardas P. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab 2005; 7: 722 – 8. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.